Health3 updates
Next-generation obesity drugs after Ozempic
What happened before and after this story. Background events not previously covered were summarised by AI.
- Background
FDA approves Wegovy, semaglutide injection, for chronic weight management
The US drug regulator cleared Novo Nordisk's weekly semaglutide injection for obesity, opening the era of GLP-1 weight-loss drugs.
- Background
FDA approves Eli Lilly's tirzepatide as Zepbound for obesity treatment
On 8 November 2023 the US FDA approved Eli Lilly's dual-action drug tirzepatide for chronic weight management, marketed as Zepbound.
After Ozempic: the next obesity drugs aim for more weight loss, less muscle loss
A review in Science looks at the next wave of obesity drugs. Generic semaglutide is already sold in India, but patents may delay it in Spain until 2031.